Tag: PER

Basel, 01 August 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo® (ranibizumab injection) for the treatment of people with nAMD.¹ Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California, United States.

Transaction in Own Shares   

SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Before the markets opened on July 25, 2025, investors in Centene Corporation (NYSE: CNC) saw the price of their shares decline about 10% in pre-market trading after the company reported disastrous Q2 2025 financial results.

Brand-New 2025 Apartment Building at 222 N Alvarado St Offers Investors Immediate Cash Flow and Premium Upside

Volta Finance Limited (VTA/VTAS)

GLENVIEW, Ill., Aug. 01, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Illinois Tool Works Inc. (NYSE: ITW) authorized a seven percent increase to the dividend payout to shareholders, representing a quarterly increase of $0.11 per share – or $0.44 per share annually – versus the current dividend rate. The Board also declared a dividend on the company's common stock of $1.61 per share for the third quarter of 2025. The dividend equates to $6.44 per share on a full-year basis. The dividend will be paid on October 10, 2025 to shareholders of record as of September 30, 2025.